Hims & Hers (HIMS) just turned a courtroom drama into a growth story and its stock has flown +40% higher today, and a little-known insulin pump maker may be quietly scripting the sequel in metabolic health.
Hims & Hers: From GLP-1 Outlaw to Ozempic Insider
In a matter of days, Hims & Hers went from defending itself against a pharma giant to becoming one of its chosen digital storefronts. Novo Nordisk (NVO) will now distribute its blockbuster weight-loss drugs, including Ozempic and Wegovy, through the Hims platform, giving the telehealth company something many rivals envy: direct access to branded GLP-1 therapies that still define the obesity gold rush.
Investors noticed immediately. Hims shares surged more than 40% on the news, as the market recalibrated the company from GLP-1 agitator to strategically indispensable partner. For Novo Nordisk, the deal is equally pragmatic; the company gains a high-traffic digital channel for its medications, aligning with its stated goal of expanding access to patients “regardless of their chosen care provider.”
A Truce That Resets the Playing Field
The partnership effectively buries a legal hatchet that had been swinging uncomfortably close to Hims’ business model. The dispute centered on compounded GLP-1 alternatives — cheaper knockoffs that Novo Nordisk argued infringed its Wegovy patents and undermined safety controls around its flagship obesity drugs. Under the new agreement, Hims will stop promoting compounded GLP-1s and help current users transition to FDA-approved options when clinically appropriate, while Novo Nordisk drops its lawsuit.
It is a rare Wall Street moment when the “copycat” gets invited into the brand house instead of thrown out of it. Yet it neatly fits Hims’ evolution: the company has been repositioning its weight-loss business as a holistic, subscription-based service rather than a race to the lowest-cost injection. Management has already highlighted weight-loss offerings as one of the fastest-growing specialties, tracking toward a nine-figure revenue run-rate, and this truce gives that trajectory a more durable foundation.
Telehealth Meets Hardware: Enter Modular Medical
While Hims and Novo Nordisk are redefining how obesity drugs reach patients, another player is working on how insulin reaches them — and how painless that experience can be. Modular Medical, trading under the ticker MODD, is preparing to launch its Pivot tubeless insulin patch pump, aiming squarely at the large population of “almost-pumpers”: adults with diabetes who still inject multiple times a day but have balked at traditional pump complexity and cost, an approximately $3 Billion Market opportunity.
Pivot is designed as a removable, tubeless 3 milliliter patch pump with a detachable two-part design that lets users remove it for showers or exercise and deliver boluses without a separate dedicated controller. The company has validated its controller manufacturing line and begun producing validation lots for cartridges and infusion sets, signaling readiness for high-volume production once regulators sign off. A 510(k) submission was filed with the FDA in November 2025, and Modular is targeting a commercial launch in the first quarter of 2026, subject to clearance.
Two Sides of the Metabolic Coin
At first glance, Hims’ GLP-1 deals and Modular’s insulin pump push might look like separate stories. In reality, they are chapters in the same narrative: the industrialization of metabolic care. Obesity drugs such as Wegovy and Ozempic have captured the headlines, but long-term diabetes management still depends on a mix of medications, devices, and data — and investors are increasingly funding the full stack.
Hims is building the demand interface: a consumer-friendly gateway that simplifies how patients discover, qualify for, and receive evidence-based therapies, now including branded GLP-1s supplied directly by Novo Nordisk. Modular is working on the delivery infrastructure: an insulin pump intended to make advanced therapy feel as simple as a patch, targeting a multibillion-dollar market of patients not yet captured by existing pump incumbents. Put together, they highlight a market moving from episodic prescription refills to continuous, device-enabled and platform-managed care.
Why Wall Street Is Listening
The appeal for investors goes beyond a single stock pop. Hims’ agreement clarifies regulatory risk around compounded GLP-1s, replaces a legal overhang with a marquee partnership, and strengthens a business line that was already outpacing the rest of the platform. For Novo Nordisk, partnering with digital clinics like Hims is a capital-light way to expand capacity and capture demand without being dragged into the compounded-drug gray zone.
Modular Medical (NASDAQ: MODD), meanwhile, is pursuing a classic medtech playbook: de-risk manufacturing ahead of approval, aim at an underserved segment, and position Pivot as a simpler, more approachable, less expensive alternative in an insulin pump category that still leaves roughly 70% of insulin-dependent adults on multiple daily injections and approximately $3 Billion Market. If the company executes on its Q1 2026 launch target and secures clearance, it will step into a global insulin pump market it estimates in the multi-billion-dollar range, with a product deliberately tuned for ease-of-use, not just engineering elegance.
In a market fixated on weight-loss miracles, the real story may be more prosaic and more durable: platforms that route the right drugs to the right patients, and devices that quietly make daily therapy less of a burden. Today that story stars Hims & Hers and Novo Nordisk; tomorrow, it may feature an unobtrusive patch pump called Pivot just as prominently.
The Sources
- Hims & Hers stock surges as Novo Nordisk says it will distribute weight-loss drugs on platform (Yahoo Finance)
https://finance.yahoo.com/news/hims–hers-stock-surges-as-novo-nordisk-says-it-will-distribute-weight-loss-drugs-on-platform-150816824.html[finance.yahoo] - Hims & Hers Announces Strategic Shift for US Weight Loss Business (Yahoo Finance)
https://finance.yahoo.com/news/hims-hers-announces-strategic-shift-123000312.html[sg.finance.yahoo] - Novo Nordisk drops lawsuit over weight loss medications, enters partnership with Hims & Hers (Yahoo / AP)
https://ca.news.yahoo.com/novo-nordisk-drops-lawsuit-over-152130028.html[ca.news.yahoo] - Hims & Hers Surprise Rescue: Stock Explodes 40% on GLP-1 Truce (Yahoo Finance)
https://finance.yahoo.com/news/hims-hers-surprise-rescue-stock-155648435.html[finance.yahoo] - Why Hims & Hers Health (HIMS) Stock Is Up Today (Finviz News)
https://finviz.com/news/333954/why-hims-hers-health-hims-stock-is-up-today[finviz] - Modular Medical Submits Pivot Tubeless Insulin Patch Pump for FDA 510(k) Clearance (Yahoo Finance / Accesswire)
https://finance.yahoo.com/news/modular-medical-submits-pivot-tubeless-140000932.html[finance.yahoo] - Modular Medical Submits Pivot Tubeless Insulin Patch Pump for FDA 510(k) Clearance (BioSpace)
https://www.biospace.com/press-releases/modular-medical-submits-pivot-tubeless-insulin-patch-pump-for-fda-510k-clearance[biospace] - Modular Medical Achieves Key Manufacturing Milestone for Pivot Tubeless Insulin Patch Pump (Accesswire via BioSpace/Yahoo)
https://finance.yahoo.com/news/modular-medical-achieves-key-manufacturing-133000481.html[finance.yahoo] - Modular Medical Achieves Key Manufacturing Milestone for Pivot Tubeless Insulin Patch Pump (news summary)
https://nationaltoday.com/us/ca/san-diego/news/2026/02/05/modular-medical-achieves-key-manufacturing-milestone-for-pivot-tubeles[nationaltoday] - Modular Medical Achieves Key Manufacturing Milestone for Pivot Tubeless Insulin Patch Pump (Accesswire full release)
https://www.biospace.com/press-releases/modular-medical-achieves-key-manufacturing-milestone-for-pivot-tubeless-insulin-patch-pu[biospace] - Modular Medical hits validation milestone for insulin patch pump (Drug Delivery Business News)
https://www.drugdeliverybusiness.com/modular-medical-validation-milestone-pivot/[drugdeliverybusiness]
